Enveric Biosciences’ (ENBI) plummeted 45% this morning after announcing a $10M public offering at 50 cents per share, about 24% below yesterday’s closing price of 66 cents 😬
Universal Ibogaine (IBO) and Osoyoos Indian Band signed an agreement to develop a detox center that combines western science and Indigenous wisdom.
The center will use ibogaine treatments to ease opioid cravings and withdrawal symptoms, followed by Indigenous healing practices as aftercare to “rebuild people in a holistic manner.”
Their flagship detox center will be in Manitoba, Canada with the goal of working with other First Nations to expand across the country, and then globally.
A wild DMT trip that blasts you off to a different dimension has potential to be therapeutic, but also very anxiety-inducing.
That’s why Cybin (CYBN) developed a version of the molecule that breaks down slowly in the body. So instead of a 10-minute rocket ride to outer space, patients have a smoother, more pleasant experience with a larger therapeutic window.
The company received a patent for the formulation this week and will study it as a treatment for anxiety disorders in Q3 of this year.
A bill was filed in Maryland to offer free psychedelic therapy to veterans with PTSD and promote psychedelic research.
Diagnosing and measuring depression is usually very subjective, relying on data from patient questionnaires. This leaves room for bias and makes it difficult to know if a treatment is actually working.
MYND Diagnostics of MYND Life Sciences (MYND) developed a biomarker test that provides objective data to solve this problem. It measures inflammation in the brain, which may be what causes depression.
Seeing evidence of improvement gives patients hope in the treatment process, like showing them the “light at the end of the tunnel” as MYND’s CEO explained on a recent Daily Mushroom Podcast.
The company announced that Monash University will use the biomarker test in a psilocybin study on treatment-resistant depression, which has received $3M in funding from the Australian government.
Maine lawmakers rejected a bill that would legalize medical use of psilocybin after an 8-3 vote. The bill’s sponsor says she’s not surprised, however “society is changing, and the science is moving quickly, so it’s a matter of when, and not if, legislation like this passes in the future.”
Activists in Washington filed an initiative to decriminalize simple drug possession statewide and give $150M in annual funding to substance abuse prevention, recovery, research, and education.
The measure could appear on the ballot this November if enough signatures are collected.
The Oregon Health Authority released the first draft of rules for the state’s legal psilocybin program. Only one of 200 species of psilocybin mushrooms will be allowed (psilocybe cubensis, the most popular species) and synthetic psilocybin will be banned. Plus, facilitators will need 120 hours of instruction on psilocybin history, safety, racial justice, and cultural equity.
A couple was on the verge of getting divorced until they took MDMA together for the first time.
The wife, Ree, said her husband couldn’t open up to her or deal with conflict, but MDMA helped them see eye-to-eye.
“My husband started sharing with me for the first time all these thoughts and emotions,” Ree said. “It was him without the walls.”
They decided to take MDMA together twice a year and go over a list of issues they want to address. Three years later, their marriage is solid and they can communicate openly without the need for drugs.
Optimi Health (OPTI) received a Dealer’s License from Health Canada and announced that it will begin cultivating, extracting, and processing “the highest-grade all-natural psilocybin in North America” at its facility in Princeton, British Columbia. The facility can secure up to 1,250kg of psilocybin, a value of roughly $53MM CDN.
